Cargando…
1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients
BACKGROUND: Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause of uncontrolled CMV reactivation and associated complications in both solid-organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Reliably assessing CMV-CMI is desirable to...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252655/ http://dx.doi.org/10.1093/ofid/ofy210.1403 |
_version_ | 1783373313444151296 |
---|---|
author | Banas, Bernhard Steubl, Dominik Renders, Lutz Chittka, Dominik Banas, Miriam Wekerle, Thomas Koch, Martina Witzke, Oliver Lindemann, Monika Muehlfeld, Anja Sommerer, Claudia Habicht, Antja Hugo, Christian Huenig, Thomas Mielke, Stephan Schreder, Martin Wagner, Eva Teschner, Daniel Klein, Stefan Heidenreich, Daniela Kreil, Sebastian Schaefer-Eckart, Kerstin Gaertner, Johannes Verbeek, Mareike Grass, Sandra Wolschke, Christine Janson, Dietlinde Kobbe, Guido Kondakci, Mustafa Ditschkowski, Markus Gromke, Tanja Hilgendorf, Inken Lilienfeld-Toal, Marie Von Schmidt, Traudel Rascle, Anne Barabas, Sascha Deml, Ludwig Wagner, Ralf Kraemer, Bernhard Krueger, Bernd Wolff, Daniel |
author_facet | Banas, Bernhard Steubl, Dominik Renders, Lutz Chittka, Dominik Banas, Miriam Wekerle, Thomas Koch, Martina Witzke, Oliver Lindemann, Monika Muehlfeld, Anja Sommerer, Claudia Habicht, Antja Hugo, Christian Huenig, Thomas Mielke, Stephan Schreder, Martin Wagner, Eva Teschner, Daniel Klein, Stefan Heidenreich, Daniela Kreil, Sebastian Schaefer-Eckart, Kerstin Gaertner, Johannes Verbeek, Mareike Grass, Sandra Wolschke, Christine Janson, Dietlinde Kobbe, Guido Kondakci, Mustafa Ditschkowski, Markus Gromke, Tanja Hilgendorf, Inken Lilienfeld-Toal, Marie Von Schmidt, Traudel Rascle, Anne Barabas, Sascha Deml, Ludwig Wagner, Ralf Kraemer, Bernhard Krueger, Bernd Wolff, Daniel |
author_sort | Banas, Bernhard |
collection | PubMed |
description | BACKGROUND: Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause of uncontrolled CMV reactivation and associated complications in both solid-organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Reliably assessing CMV-CMI is desirable to individually adjust antiviral and immunosuppressive therapy. We demonstrate here the suitability of a novel IFN-γ ELISpot assay (T-Track(®) CMV), based on the stimulation of PBMC with pp65 and IE-1 CMV proteins, to monitor CMV-CMI in SOT and HSCT patients. METHODS: Two independent prospective, longitudinal, observational, multicenter studies were conducted: in 86 intermediate-risk (D−/R+, D+/R+) renal transplant recipients (completed), and in 175 intermediate- or high-risk (D+/R+, D+/R−, D−/R+) HSCT recipients (ongoing). In both studies, patients underwent pre-emptive antiviral therapy. CMV-CMI, CMV load and clinical complications were monitored over ~6 months post-transplantation. RESULTS: In the kidney transplantation setting, 95% and 88–92% of IFN-γ ELISpot test results were positive pre- and post-transplantation, respectively. CMV-specific response was reduced following immunosuppressive therapy and increased in patients with graft rejection, indicating the ability of the assay to monitor the patients’ immunosuppressive state. Interestingly, median pp65-specific response was 9-fold higher in patients with self-clearing viral load compared with antivirally-treated patients prior to first detection of CMV (MWU; P < 0.001), suggesting that reactivity to pp65 is a potential immunocompetence marker. In HSCT patients, interim data analysis indicates that pp65-specific CMI measured after resolution of a primary CMV reactivation (requiring antiviral treatment) is a fair predictor of occurrence of recurrent CMV reactivation. Out of 71 patients (25 D+/R+, 3 D+/R−, 43 D−/R+) who experienced a primary CMV reactivation, 27 encountered a recurrent CMV reactivation. Interestingly, 39/44 (89%) patients free of recurrent reactivation had a positive pp65-specific test result following primary CMV reactivation. CONCLUSION: Altogether, this novel IFN-γ ELISpot assay is a highly sensitive immune-monitoring tool with a potential use for the risk assessment of CMV-related clinical complications after SOT and HSCT. DISCLOSURES: All authors, Lophius Biosciences: Investigator, Research support. |
format | Online Article Text |
id | pubmed-6252655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62526552018-11-28 1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients Banas, Bernhard Steubl, Dominik Renders, Lutz Chittka, Dominik Banas, Miriam Wekerle, Thomas Koch, Martina Witzke, Oliver Lindemann, Monika Muehlfeld, Anja Sommerer, Claudia Habicht, Antja Hugo, Christian Huenig, Thomas Mielke, Stephan Schreder, Martin Wagner, Eva Teschner, Daniel Klein, Stefan Heidenreich, Daniela Kreil, Sebastian Schaefer-Eckart, Kerstin Gaertner, Johannes Verbeek, Mareike Grass, Sandra Wolschke, Christine Janson, Dietlinde Kobbe, Guido Kondakci, Mustafa Ditschkowski, Markus Gromke, Tanja Hilgendorf, Inken Lilienfeld-Toal, Marie Von Schmidt, Traudel Rascle, Anne Barabas, Sascha Deml, Ludwig Wagner, Ralf Kraemer, Bernhard Krueger, Bernd Wolff, Daniel Open Forum Infect Dis Abstracts BACKGROUND: Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause of uncontrolled CMV reactivation and associated complications in both solid-organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Reliably assessing CMV-CMI is desirable to individually adjust antiviral and immunosuppressive therapy. We demonstrate here the suitability of a novel IFN-γ ELISpot assay (T-Track(®) CMV), based on the stimulation of PBMC with pp65 and IE-1 CMV proteins, to monitor CMV-CMI in SOT and HSCT patients. METHODS: Two independent prospective, longitudinal, observational, multicenter studies were conducted: in 86 intermediate-risk (D−/R+, D+/R+) renal transplant recipients (completed), and in 175 intermediate- or high-risk (D+/R+, D+/R−, D−/R+) HSCT recipients (ongoing). In both studies, patients underwent pre-emptive antiviral therapy. CMV-CMI, CMV load and clinical complications were monitored over ~6 months post-transplantation. RESULTS: In the kidney transplantation setting, 95% and 88–92% of IFN-γ ELISpot test results were positive pre- and post-transplantation, respectively. CMV-specific response was reduced following immunosuppressive therapy and increased in patients with graft rejection, indicating the ability of the assay to monitor the patients’ immunosuppressive state. Interestingly, median pp65-specific response was 9-fold higher in patients with self-clearing viral load compared with antivirally-treated patients prior to first detection of CMV (MWU; P < 0.001), suggesting that reactivity to pp65 is a potential immunocompetence marker. In HSCT patients, interim data analysis indicates that pp65-specific CMI measured after resolution of a primary CMV reactivation (requiring antiviral treatment) is a fair predictor of occurrence of recurrent CMV reactivation. Out of 71 patients (25 D+/R+, 3 D+/R−, 43 D−/R+) who experienced a primary CMV reactivation, 27 encountered a recurrent CMV reactivation. Interestingly, 39/44 (89%) patients free of recurrent reactivation had a positive pp65-specific test result following primary CMV reactivation. CONCLUSION: Altogether, this novel IFN-γ ELISpot assay is a highly sensitive immune-monitoring tool with a potential use for the risk assessment of CMV-related clinical complications after SOT and HSCT. DISCLOSURES: All authors, Lophius Biosciences: Investigator, Research support. Oxford University Press 2018-11-26 /pmc/articles/PMC6252655/ http://dx.doi.org/10.1093/ofid/ofy210.1403 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Banas, Bernhard Steubl, Dominik Renders, Lutz Chittka, Dominik Banas, Miriam Wekerle, Thomas Koch, Martina Witzke, Oliver Lindemann, Monika Muehlfeld, Anja Sommerer, Claudia Habicht, Antja Hugo, Christian Huenig, Thomas Mielke, Stephan Schreder, Martin Wagner, Eva Teschner, Daniel Klein, Stefan Heidenreich, Daniela Kreil, Sebastian Schaefer-Eckart, Kerstin Gaertner, Johannes Verbeek, Mareike Grass, Sandra Wolschke, Christine Janson, Dietlinde Kobbe, Guido Kondakci, Mustafa Ditschkowski, Markus Gromke, Tanja Hilgendorf, Inken Lilienfeld-Toal, Marie Von Schmidt, Traudel Rascle, Anne Barabas, Sascha Deml, Ludwig Wagner, Ralf Kraemer, Bernhard Krueger, Bernd Wolff, Daniel 1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients |
title | 1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients |
title_full | 1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients |
title_fullStr | 1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients |
title_full_unstemmed | 1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients |
title_short | 1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients |
title_sort | 1575. clinical validation of a novel elispot-based in vitro diagnostic assay to monitor cmv-specific cell-mediated immunity in sot and hsct immunocompromised patients |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252655/ http://dx.doi.org/10.1093/ofid/ofy210.1403 |
work_keys_str_mv | AT banasbernhard 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT steubldominik 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT renderslutz 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT chittkadominik 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT banasmiriam 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT wekerlethomas 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT kochmartina 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT witzkeoliver 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT lindemannmonika 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT muehlfeldanja 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT sommererclaudia 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT habichtantja 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT hugochristian 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT huenigthomas 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT mielkestephan 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT schredermartin 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT wagnereva 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT teschnerdaniel 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT kleinstefan 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT heidenreichdaniela 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT kreilsebastian 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT schaefereckartkerstin 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT gaertnerjohannes 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT verbeekmareike 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT grasssandra 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT wolschkechristine 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT jansondietlinde 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT kobbeguido 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT kondakcimustafa 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT ditschkowskimarkus 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT gromketanja 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT hilgendorfinken 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT lilienfeldtoalmarievon 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT schmidttraudel 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT rascleanne 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT barabassascha 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT demlludwig 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT wagnerralf 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT kraemerbernhard 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT kruegerbernd 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients AT wolffdaniel 1575clinicalvalidationofanovelelispotbasedinvitrodiagnosticassaytomonitorcmvspecificcellmediatedimmunityinsotandhsctimmunocompromisedpatients |